Preapproval Inspections: Industry Urges FDA Transition To “For Cause”
Executive Summary
FDA should consider moving to "for cause" preapproval inspections as part of its quality systems initiative, drug manufacturers told FDA at the Product Quality Research Institute/FDA conference in Washington, D.C. April 24
You may also be interested in...
GMP Dispute Resolution Draft Guidance To Issue In Next Few Months
FDA expects to issue a draft guidance in the coming months on a formal dispute resolution process for scientific and technical issues that arise during inspections
GMP Dispute Resolution Draft Guidance To Issue In Next Few Months
FDA expects to issue a draft guidance in the coming months on a formal dispute resolution process for scientific and technical issues that arise during inspections
BIO Petition Opposes Generic Insulin, HGH; Asks FDA To Open Public Debate
The Biotechnology Industry Organization is asking FDA to initiate a public comment process on generic biologics before it moves forward in creating approval pathways for generic therapeutic proteins